Tacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments

被引：20

作者：

Bautista-Aguilera, Oscar M. ^{[1
]}

Ismaili, Lhassane ^{[2
]}

Iriepa, Isabel ^{[1
,3
]}

Diez-Iriepa, Daniel ^{[1
]}

Chabchoub, Fakher ^{[4
]}

Marco-Contelles, Jose ^{[5
]}

Perez, Marta ^{[6
]}

机构：

[1] Univ Alcala, Dept Quim Organ & Quim Inorgan, Ctra Madrid Barcelona,Km 33,6, Madrid 28871, Spain

[2] Univ Bourgogne Franche Comte, Lab Chim Organ & Therapeut, Neurosci Integrat & Clin EA 481, UFR Sante, 19 Rue Ambroise Pare, F-25000 Besancon, France

[3] Alcala Univ, Inst Chem Res Andres M del Rio, Madrid 28805, Spain

[4] Univ Sfax, Lab Chim Appl Heterocycles Corps Gras & Polymeres, Fac Sci Sfax, BP 802, Sfax 3000, Tunisia

[5] CSIC, Lab Med Chem IQOG, Juan de la Cierva 3, Madrid 28006, Spain

[6] Univ Basque Country, Publ Hlth Dept, Fac Med & Nursing, Leioa, Spain

来源：

CHEMICAL RECORD | 2021年 / 21卷 / 01期

关键词：

Alzheimer' s disease; Cholinesterase inhibition; Friedlä nder reaction; Hepatotoxicity; Tacrine derivatives; BIOLOGICAL ASSESSMENT; DIRECTED LIGANDS; SENILE DEMENTIA; ACETYLCHOLINESTERASE; INHIBITORS; DRUGS; FLUORESCEIN; MELATONIN; HYBRIDS; DESIGN;

D O I：

10.1002/tcr.202000107

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Herein we have reviewed our recent developments for the identification of new tacrine analogues for Alzheimer's disease (AD) therapy. Tacrine, the first cholinesterase inhibitor approved for AD treatment, did not stop the progression of AD, producing only some cognitive improvements, but exhibited secondary effects mainly due to its hepatotoxicity. Thus, the drug was withdrawn from the clinics administration. Since then, many publications have described non-hepatotoxic tacrines, and in addition, important efforts have been made to design multitarget tacrines by combining their cholinesterase inhibition profile with the modulation of other biological targets involved in AD.

引用

页码：162 / 174

页数：13

共 50 条

[1] Tacrines as Therapeutic Agents for Alzheimer's Disease. IV. The Tacripyrines and Related Annulated Tacrines
Bartolini, Manuela
Marco-Contelles, Jose
[J]. CHEMICAL RECORD, 2019, 19 (05): : 927 - 937
[2] Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines
Romero, Alejandro
Marco-Contelles, Jose
[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (31) : 3328 - 3335
[3] Recent developments in Alzheimer's disease
Cras, P
[J]. ACTA CLINICA BELGICA, 2001, 56 (05) : 269 - 278
[4] Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Teeba Athar
K. Al Balushi
Shah Alam Khan
[J]. Molecular Biology Reports, 2021, 48 : 5629 - 5645
[5] New developments in animal models of Alzheimer's disease.
Janus C.
Phinney A.L.
Chishti M.A.
Westaway D.
[J]. Current Neurology and Neuroscience Reports, 2001, 1 (5) : 451 - 457
[6] Therapeutics of Alzheimer's Disease: Recent Developments
Burns, Scott
Selman, Ashley
Sehar, Ujala
Rawat, Priyanka
Reddy, Arubala P.
Reddy, P. Hemachandra
[J]. ANTIOXIDANTS, 2022, 11 (12)
[7] Recent Developments in the Treatment of Alzheimer's Disease
Leon J. Thal
[J]. 上海精神医学, 1992, (S1) : 54 - 58
[8] Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease
Athar, Teeba
Al Balushi, K.
Khan, Shah Alam
[J]. MOLECULAR BIOLOGY REPORTS, 2021, 48 (07) : 5629 - 5645
[9] Recent developments in Alzheimer's disease therapeutics
Rafii, Michael S.
Aisen, Paul S.
[J]. BMC MEDICINE, 2009, 7
[10] Alzheimer's disease: A review of recent developments
Salawu, Fatai K.
Umar, Joel T.
Olokoba, Abdulfatai B.
[J]. ANNALS OF AFRICAN MEDICINE, 2011, 10 (02) : 73 - 79

← 1 2 3 4 5 →